BCLI
Brainstorm Cell Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.05
−1.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 131.0K | — | 240.0K | 265.0K | 285.0K |
| Gross Profit | (131.0K) | — | (240.0K) | (265.0K) | (285.0K) |
| Operating Expenses | |||||
| R&D Expense | (782.0K) | 4.2M | 4.4M | 10.5M | 14.0M |
| SG&A Expense | 696.0K | 5.8M | 7.0M | 10.7M | 10.9M |
| General & Admin Expense | (2.0M) | 5.8M | 7.0M | 10.7M | 10.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 9.9M | — | 240.0K | — | — |
| Total Operating Expenses | 9.8M | 10.0M | 11.7M | 21.2M | 24.8M |
| Cost and Expenses | 9.9M | 10.0M | 11.7M | 21.4M | 24.8M |
| Operating Income (EBIT) | (9.9M) | (10.0M) | (11.7M) | (21.4M) | (24.8M) |
| Non-Operating | |||||
| Interest Income | (46.0K) | — | — | — | 545.0K |
| Interest Expense | (7.0K) | — | 77.0K | — | — |
| Net Interest Income | (98.0K) | (533.0K) | (77.0K) | (278.0K) | 545.0K |
| Other Non-Op Income/Expense | (572.0K) | (354.0K) | 70.0K | 4.2M | 545.0K |
| Non-Operating Income (excl Interest) | — | — | (147.0K) | (4.2M) | (545.0K) |
| EBT (Pre-Tax Income) | (10.5M) | (10.3M) | 11.6M | (17.2M) | (24.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.5M) | (10.3M) | 11.6M | (17.2M) | (24.3M) |
| Earnings from Cont. Ops | (10.5M) | (10.3M) | 11.6M | (17.2M) | (24.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.5M) | (10.3M) | 11.6M | (17.2M) | (24.3M) |
| Per Share | |||||
| Basic EPS | ($0.95) | ($1.11) | $2.19 | ($4.48) | ($9.93) |
| Diluted EPS | ($0.95) | ($1.11) | $2.19 | ($4.48) | ($9.93) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 11.0M | 9.3M | 5.3M | 3.8M | 2.4M |
| Diluted Shares Outstanding | 11.0M | 9.3M | 5.3M | 3.8M | 2.4M |
| Profitability Metrics | |||||
| EBITDA | (9.8M) | (9.8M) | (11.3M) | (16.9M) | (24.0M) |
| D&A | 179.0K | 199.0K | 240.0K | 265.0K | 285.0K |
| EBIT | (9.9M) | (10.0M) | (11.5M) | (17.2M) | (24.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026